Parenteral cytotoxic agents are among the most highly sophisticated and sensitive drugs to handle and produce. Utilizing RABS (Restricted Access Barrier System) for commercial manufacturing helps BioPharma Solutions to maintain a high level of containment while a product is being manufactured. In addition, this technology helps to maintain the integrity of the molecule, enhance product sterility and ensure the safety of the line operators.
At our recently expanded cytotoxic contract manufacturing facility in Halle/Westfalen, Germany, all your cytotoxic parenteral needs are handled at one manufacturing facility, which allows us to create efficient processing solutions to fit your compound. A dedicated cytotoxic focus helps manage capacity and flexibility, which are critical for maintaining reliable product supply.
For cytotoxic molecules, we offer the following capabilities:
•Liquid and dry-powder filling
•Clinical and commercial-scale lyophilizers
•Flexible compounding areas
•Disperse Systems - Formulation and subsequent filling/lyophilization of colloidal drug carriers, e.g. liposomes, micelles, nanoparticles, microemulsions
- Technology portfolio: Homogenization (piston-gap, microfluidization, membrane extrusion), diafiltration, organic solvent distillation, liposome direct and remote loading, sterilizing filtration